Combination therapeutic regimen is becoming a primary direction for current
cancer immunotherapy to broad the antitumor response. Functional nanomaterials offer great potential for steady codelivery of various drugs, especially small molecules, therapeutic
peptides, and
nucleic acids, thereby realizing controllable drug release, increase of drug bioavailability, and reduction of adverse effects. Herein, a therapeutic
peptide assembling nanoparticle that can sequentially respond to dual stimuli in the
tumor extracellular matrix was designed for
tumor-targeted delivery and on-demand release of a short d-
peptide antagonist of programmed cell death-
ligand 1 (DPPA-1) and an inhibitor of idoleamine 2,3-dioxygenase (
NLG919). By concurrent blockade of immune checkpoints and
tryptophan metabolism, the nanoformulation increased the level of
tumor-infiltrated cytotoxic T cells and in turn effectively inhibited
melanoma growth. To achieve this, an amphiphilic
peptide, consisting of a functional 3-diethylaminopropyl
isothiocyanate (DEAP) molecule, a
peptide substrate of
matrix metalloproteinase-2 (MMP-2), and DPPA-1, was synthesized and coassembled with
NLG919. The nanostructure swelled when it encountered the weakly acidic
tumor niche where DEAP molecules were protonated, and further collapsed due to the cleavage of the
peptide substrate by MMP-2 that is highly expressed in
tumor stroma. The localized release of DPPA-1 and
NLG919 created an environment which favored the survival and activation of cytotoxic T lymphocytes, leading to the slowdown of
melanoma growth and increase of overall survival. Together, this study offers new opportunities for dual-targeted
cancer immunotherapy through functional
peptide assembling nanoparticles with design features that are sequentially responsive to the multiple hallmarks of the tumor microenvironment.